Address: Unit 1104, Level 11 Uptown 2, No. 2, Jalan SS21/37 Damansara Uptown 47400 Petaling Jaya, Selangor,Malaysia
Tel: +60 3 7724 6200
Web: http://www.parexel.com/about/global-presence/asia-pacific/malaysia/
Over the past 27 years, PAREXEL has developed significant expertise to assist clients in the worldwide pharmaceutical, biotechnology and medical device industries with the development and launch of their products in order to bring safe and effective treatments to the global marketplace for the patients who need them. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 54 countries around the world, and has over 9,500 employees.
We are a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.
PAREXEL has been providing strategic pharmaceutical research and development services for the biopharmaceutical and medical device industries for more than 25 years. Our unsurpassed global network of in-depth expertise, clinical resources, and technology makes us the partner of choice for your complete development needs across every phase of the product lifecycle… every therapeutic area… and every geographic region. Our broad range of services includes:
Early stage development and proof-of-concept studies
Complete Phase III clinical research capabilities, with innovative site and patient recruitment approaches
Risk management and pharmacovigilance programs
Global pharmaceutical regulations compliance, pricing, and marketing strategies
Biosimilar product development
Industry-leading eClinical and medical imaging technologies
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
Eurasia Group’s Aditya Bhattacharji discusses the relatively modest scope of Malaysia’s recently-launched ‘MYSalam’ scheme; a healthcare programme which aims to provide coverage to the country’s bottom 40 percent of earners.…
After 61 years of single-party rule, the May 2018 electoral victory of the populist Pakatan Harapan (PH) coalition sent shockwaves through the Malaysian political landscape. This has been keenly felt…
Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to…
American medtech giant Baxter and pan-Asian healthcare service provider Zuellig Pharma have been collaborating in Malaysia to increase the quality and quantity of care that can be given to patients…
Sherene Azli, CEO of the Malaysia Healthcare Travel Council (MHTC), introduces this unique organization in charge of promoting Malaysia internationally as the ‘Cardiology and Fertility Hub of Asia’ and explains…
Rashidah Ibrahim, executive director of Malaysian Vaccines & Pharmaceuticals (MVP), tells the story of MVP as the sole animal vaccines manufacturer in Malaysia. She also explains how important animal health…
Chuwn Leong Ch’ng, CEO of Thunder Print, presents his company’s strategic role within the Malaysian healthcare industry to provide a high-quality packaging services for all type of health products, from…
Robert Kruit, chief executive for Zuellig Malaysia and Brunei, discusses Zuellig’s plans to expand beyond distribution and diversify its offering in the healthcare sector, and how Zuellig’s investments into digital…
Tan Sri Dato’ Ariffin Yusuf, founder and managing director of Primabumi, explains how he came to build Primabumi in 1975 and how he managed to position the company as a…
Halal pharmaceuticals – medicines that do not contain any alcohol, parts of animals such as dogs, pigs, bees, or any other substances prohibited as ‘haram’ under Shariah law – are…
Lee Yee Keng, head of healthcare sector of KPMG in Malaysia, highlights the opportunities Malaysia can offer to the healthcare industry, including its potential for private-public partnerships, and how the…
See our Cookie Privacy Policy Here
